← Leaderboards
Vivien Jane Coulson-Thomas
University Of Houston
$4,727,687
Attributed
$4,951,749
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,951,749 · 4
By mechanism
R01$4,071,874 · 2
R21$879,875 · 2
Top collaborators
- Cintia Sade De Paiva2 shared
Others in their field
Other Emerging Leaders on “Wild Type Mouse”
- James Even Voss · Scripps Research Institute, The$8,004,325
- Kevin Wiehe · Duke University$7,046,198
- Charles Bernick · Athira Pharma, Inc.$6,312,103
- Hans Joerg Moebius · Athira Pharma, Inc.$6,312,103
- Thomas Dick · Rbhs-New Jersey Medical School$6,021,400
- Bing Yao · Emory University$4,719,951
Research focus
Wild Type MouseKnockout MiceDesignPainStem CellsHyaluronanComplexCellsMacromoleculeExtracellular MatrixHas2 GenePhysiologicalBlindnessPublishingHas3 GeneBindingHyaluronan Synthase 1Up-RegulationInflammationLeadInjuryCorneaMedicalPlay
Grant awards (16)
Hyaluronan in the limbal stem cell niche: from regulation of stem cell fate to translational applications$496,301
R01 · FY2025 · EY · contact PI
Identifying the mechanism(s) of scarless corneal wound healing in Acomys cahirinus (The African Spiny mice) and Mus musculus$431,750
R21 · FY2025 · EY · contact PI
Modifying the extracellular matrix to prevent dry eye disease and age-related Meibomian gland dysfunction (ARMGD)$387,500
R01 · FY2025 · EY · contact PI
Pathobiology of autoimmune Meibomian gland dysfunction$196,875
R21 · FY2025 · EY
Modifying the extracellular matrix to prevent dry eye disease and age-related Meibomian gland dysfunction (ARMGD)$387,500
R01 · FY2024 · EY · contact PI
Pathobiology of autoimmune Meibomian gland dysfunction$251,250
R21 · FY2024 · EY
Modifying the extracellular matrix to prevent dry eye disease and age-related Meibomian gland dysfunction (ARMGD)$401,864
R01 · FY2023 · EY · contact PI
Modifying the extracellular matrix to prevent dry eye disease and age-related Meibomian gland dysfunction (ARMGD)$387,500
R01 · FY2022 · EY · contact PI
Hyaluronan in the cornea: Regulation of limbal stem cell fate and lymphangiogenesis$371,025
R01 · FY2022 · EY · contact PI
Hyaluronan in the cornea: Regulation of limbal stem cell fate and lymphangiogenesis$50,758
R01 · FY2022 · EY · contact PI
Hyaluronan in the cornea: Regulation of limbal stem cell fate and lymphangiogenesis$371,025
R01 · FY2021 · EY · contact PI
Hyaluronan in the cornea: Regulation of limbal stem cell fate and lymphangiogenesis$49,235
R01 · FY2021 · EY · contact PI
Hyaluronan in the cornea: Regulation of limbal stem cell fate and lymphangiogenesis$21,666
R01 · FY2021 · EY · contact PI
Hyaluronan in the cornea: Regulation of limbal stem cell fate and lymphangiogenesis$382,500
R01 · FY2020 · EY · contact PI
Hyaluronan in the cornea: Regulation of limbal stem cell fate and lymphangiogenesis$382,500
R01 · FY2019 · EY · contact PI
Hyaluronan in the cornea: Regulation of limbal stem cell fate and lymphangiogenesis$382,500
R01 · FY2018 · EY · contact PI